Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction

Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000 · see citing works

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · see citing works

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2× · see citing works

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis

Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · see citing works

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014 · see citing works

Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism

Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · see citing works

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works

Excess Mortality among Persons with Type 2 Diabetes

Tancredi, M., Rosengren, A., Svensson, A., Kosiborod, M., Pivodic, A., Guðbjörnsdóttir, S., Wedel, H., Clements, M. A., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 996 · see citing works

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · see citing works

Pathophysiology of diabetic dyslipidaemia: where are we?

Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708 · see citing works

Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)

Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · see citing works

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551 · see citing works

Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study

Hoogeveen, R. C., Gaubatz, J. W., Sun, W., Dodge, R. C., Crosby, J. R., Jiang, J., Couper, D., Virani, S. S., Kathiresan, S., Boerwinkle, E., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303284 · Cited by 507 · see citing works

Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport

Jia, L., Betters, J. L., & Yu, L. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142233 · Cited by 384 · see citing works

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 339 · see citing works

Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 216 · see citing works

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208 · see citing works

Serum Level of Triglycerides Is a Potent Risk Factor Comparable to LDL Cholesterol for Coronary Heart Disease in Japanese Patients with Type 2 Diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS)

Sone, H., Tanaka, S., Tanaka, S., Iimuro, S., Oida, K., Yamasaki, Y., Oikawa, S., Ishibashi, S., Katayama, S., Ohashi, Y., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0622 · Cited by 201 · see citing works

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184 · see citing works

Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes

Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170 · see citing works

Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann–Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein

Lally, S., Tan, C. Y., Owens, D., & Tomkin, G. (2006) · Diabetologia · doi:10.1007/s00125-006-0177-8 · Cited by 146 · see citing works

Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

Bajaj, M., Suraamornkul, S., Hardies, L. J., Glass, L. C., Musi, N., & DeFronzo, R. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0698-9 · Cited by 138 · see citing works

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

Hennuyer, N., Duplan, I., Paquet, C., Vanhoutte, J., Woitrain, E., Touche, V., Colin, S., Vallez, E., Lestavel, S., Lefebvre, P., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.003 · Cited by 132 · see citing works

Effects of a Potent and Selective PPAR-α Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia

Nissen, S. E., Nicholls, S. J., Wolski, K., Howey, D. C., McErlean, E. S., Wang, M.-D., Gomez, E. V., & Russo, J. (2007) · JAMA · doi:10.1001/jama.297.12.1362 · Cited by 130 · see citing works

Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124 · see citing works

Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver

Raza-Iqbal, S., Tanaka, T., Anai, M., Inagaki, T., Matsumura, Y., Ikeda, K., Taguchi, A., Gonzalez, F. J., Sakai, J., & Kodama, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.28720 · Cited by 100 · see citing works

Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database

Mulnier, H. E., Seaman, H. E., Raleigh, V. S., Soedamah‐Muthu, S. S., Colhoun, H. M., Lawrenson, R. A., & de Vries, C. S. (2008) · Diabetologia · doi:10.1007/s00125-008-1076-y · Cited by 79 · see citing works

Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients

Taniguchi, A., Fukushima, M., Sakai, M., Tokuyama, K., Nagata, I., Fukunaga, A., Kishimoto, H., Doi, K., Yamashita, Y., Matsuura, T., et al. (2001) · Metabolism · doi:10.1053/meta.2001.21028 · Cited by 60 · see citing works

Pemafibrate: First Global Approval

Blair, H. A. (2017) · Drugs · doi:10.1007/s40265-017-0818-x · Cited by 54 · see citing works

Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice

Takei, K., Nakagawa, Y., Wang, Y., Han, S.-I., Satoh, A., Sekiya, M., Matsuzaka, T., & Shimano, H. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.02.003 · Cited by 43 · see citing works

Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

Millar, J. S., Duffy, D., Gadi, R., Bloedon, L. T., Dunbar, R. L., Wolfe, M. L., Movva, R., Shah, A., Fuki, I. V., McCoy, M., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.171223 · Cited by 42 · see citing works

Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice

Takei, K., Han, S.-I., Murayama, Y., Satoh, A., Oikawa, F., Ohno, H., Osaki, Y., Matsuzaka, T., Sekiya, M., Iwasaki, H., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12621 · Cited by 39 · see citing works

The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial

Black, N., Ennis, C. N., Young, I. S., Hunter, S. J., Atkinson, A. B., & Bell, P. M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.001 · Cited by 23 · see citing works

Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression

Singh, J. P., Kauffman, R. F., Bensch, W. R., Wang, G.-M., McClelland, P., Bean, J. S., Montrose, C., Mantlo, N. B., & Wagle, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.010991 · Cited by 22 · see citing works

Fenofibrate Reduces Postprandial Hypertriglyceridemia in CD36 Knockout Mice

Sandoval, J. C., Nakagawa-Toyama, Y., Masuda, D., Tochino, Y., Nakaoka, H., Kawase, R., Yuasa‐Kawase, M., Nakatani, K., Inagaki, M., Tsubakio‐Yamamoto, K., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.3988 · Cited by 17 · see citing works

Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study

Shiochi, H., Ohkura, T., Fujioka, Y., Sumi, K., Yamamoto, N., Nakanishi, R., Matsuzawa, K., Izawa, S., Ohkura, H., Inoue, K., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-113 · Cited by 10 · see citing works

Abstract 12867: The Mechanism of K-877, a Highly Potent and Selective Pparalpha Modulator, on Regulation of Synthesis, Secretion and Metabolism of Triglycerides and Cholesterol

Takizawa, T., Inokuchi, Y., Goto, S., Yoshinaka, Y., Abe, K., Inoue, K., & Tanabe, S. (2013) · Circulation · Cited by 9 · see citing works

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works

PPAR control of metabolism and cardiovascular functions

Montaigne, D., Butruille, L., & Staels, B. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00569-6 · Cited by 960 · see citing works

Molecular Actions of PPARα in Lipid Metabolism and Inflammation

Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898 · see citing works

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749 · see citing works

Clinical review on triglycerides

Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544 · see citing works

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319 · see citing works

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315 · see citing works

Cardiomyopathy in obesity, insulin resistance and diabetes

Nakamura, M., & Sadoshima, J. (2019) · The Journal of Physiology · doi:10.1113/jp276747 · Cited by 287 · see citing works

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

Cheng, H. S., Tan, W., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 272 · see citing works

PPAR Agonists and Metabolic Syndrome: An Established Role?

Botta, M., Audano, M., Sahebkar, A., Sirtori, C. R., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253 · see citing works

Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management

Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195 · see citing works

Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases

Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191 · see citing works

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

Cariou, B., Byrne, C. D., Loomba, R. S., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 174 · see citing works

Lipid-Lowering Agents: Targets Beyond PCSK9

Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171 · see citing works

Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease

Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 147 · see citing works

Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141 · see citing works

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140 · see citing works

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy

Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 114 · see citing works

The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD

Dixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 114 · see citing works

Treating NASH by targeting peroxisome proliferator-activated receptors

Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 111 · see citing works

The Diagnosis and Treatment of Hypertriglyceridemia

Parhofer, K. G., & Laufs, U. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0825 · Cited by 110 · see citing works

The Lipid Profiles in Different Characteristics of Women with PCOS and the Interaction Between Dyslipidemia and Metabolic Disorder States: A Retrospective Study in Chinese Population

Guo, F., Gong, Z., Fernando, T., Zhang, L., Zhu, X., & Shi, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892125 · Cited by 107 · see citing works

Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions

Jin, P., Duan, X., Huang, Z., Dong, Y., Zhu, J., Guo, H., Tian, H., Zou, C., & Xie, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02270-3 · Cited by 86 · see citing works

Circulating FGF21 Levels in Human Health and Metabolic Disease

Keuper, M., Häring, H., & Staiger, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0879-2968 · Cited by 82 · see citing works

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 81 · see citing works

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79 · see citing works

The PPAR–microbiota–metabolic organ trilogy to fine‐tune physiology

Oh, H. Y. P., Visvalingam, V., & Wahli, W. (2019) · The FASEB Journal · doi:10.1096/fj.201802681rr · Cited by 78 · see citing works

Mechanisms of Abnormal Lipid Metabolism in the Pathogenesis of Disease

Xu, L., Yang, Q., & Zhou, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158465 · Cited by 71 · see citing works

A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)

Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 70 · see citing works

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 68 · see citing works

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

Ida, S., Kaneko, R., & Murata, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0845-x · Cited by 61 · see citing works

Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes

Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 60 · see citing works

Benefits and risks of the treatment with fibrates––a comprehensive summary

Okopień, B., Bułdak, Ł., & Bołdys, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1537780 · Cited by 55 · see citing works

MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists

Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 54 · see citing works

Future perspectives of the pharmacological management of diabetic dyslipidemia

Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 54 · see citing works

The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment

Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 52 · see citing works

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia

Yamashita, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.010 · Cited by 51 · see citing works

Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia

Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 49 · see citing works

Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model

Tomita, Y., Ozawa, N., Miwa, Y., Ishida, A., Ohta, M., Tsubota, K., & Kurihara, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235878 · Cited by 49 · see citing works

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48 · see citing works

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

Yamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225537 · Cited by 48 · see citing works

Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?

Dijk, W., May, C. L., & Cariou, B. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.013 · Cited by 47 · see citing works

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13686 · Cited by 46 · see citing works

Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy

Tomita, Y., Lee, D., Miwa, Y., Jiang, X., Ohta, M., Tsubota, K., & Kurihara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176243 · Cited by 46 · see citing works

Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α

Sáez-Orellana, F., Octave, J., & Pierrot, N. (2020) · Cells · doi:10.3390/cells9051215 · Cited by 45 · see citing works

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Yokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 45 · see citing works

Role of Vitamin B12 and Folate in Metabolic Syndrome

Ashok, T., Puttam, H., Tarnate, V. C. A., Jhaveri, S., Avanthika, C., Treviño, A. G. T., Sandeep, S. L., & Ahmed, N. (2021) · Cureus · doi:10.7759/cureus.18521 · Cited by 43 · see citing works

Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease

Pu, Y., Cheng, C. K., Zhang, H., Luo, J., Wang, L., Tomlinson, B., & Huang, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21970 · Cited by 42 · see citing works

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis

Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 40 · see citing works

Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia

Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 39 · see citing works

Effect of Lactobacillus fermentum TKSN041 on improving streptozotocin-induced type 2 diabetes in rats

Zhou, X., Shang, G., Tan, Q., He, Q., Tan, X., Park, K., & Zhao, X. (2021) · Food & Function · doi:10.1039/d1fo01571k · Cited by 39 · see citing works

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate

Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., & Kodama, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225682 · Cited by 38 · see citing works

Strain-Specific Effects of Bifidobacterium longum on Hypercholesterolemic Rats and Potential Mechanisms

Jiang, J., Wu, C., Zhang, C., Zhang, Q., Yu, L., Zhao, J., Zhang, H., Narbad, A., Chen, W., & Zhai, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031305 · Cited by 37 · see citing works

Synthesis of Fructose Biosensors and Progressing Their Efficiency Using Californium Colloidal Nanoparticles for Detecting Fructose and Triglycerides

Heidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 36 · see citing works

Recent advances in synthetic pharmacotherapies for dyslipidaemias

Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34 · see citing works

Diabetic dyslipidaemia

Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 33 · see citing works

Triglycerides and endothelial function: molecular biology to clinical perspective

Kajikawa, M., & Higashi, Y. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000630 · Cited by 29 · see citing works

DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism

Furukawa, N., Koitabashi, N., Matsui, H., Sunaga, H., Umbarawan, Y., Syamsunarno, M. R. A. A., Yamaguchi, A., Obokata, M., Hanaoka, H., Yokoyama, T., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01711-z · Cited by 29 · see citing works

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

Fruchart, J., Hermans, M. P., Fruchart‐Najib, J., & Kodama, T. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00897-x · Cited by 29 · see citing works

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study

Hatanaka, T., Kakizaki, S., Saito, N., Nakano, Y., Nakano, S., Hazama, Y., Yoshida, S., Hachisu, Y., Tanaka, Y., Kashiwabara, K., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6574-20 · Cited by 29 · see citing works

Retinal degeneration induced in a mouse model of ischemia–reperfusion injury and its management by pemafibrate treatment

Lee, D., Nakai, A., Miwa, Y., Tomita, Y., Kunimi, H., Chen, J., Ikeda, S., Tsubota, K., Negishi, K., & Kurihara, T. (2022) · The FASEB Journal · doi:10.1096/fj.202200455rrr · Cited by 27 · see citing works

Sex-regulated gene dosage effect of PPARα on synaptic plasticity

Pierrot, N., Ris, L., Stancu, I., Doshina, A., Ribeiro, F., Tyteca, D., Baugé, E., Lalloyer, F., Malong, L., Schakman, O., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800262 · Cited by 27 · see citing works

Effects of Fructose or Glucose on Circulating ApoCIII and Triglyceride and Cholesterol Content of Lipoprotein Subfractions in Humans

Hieronimus, B., Griffen, S. C., Keim, N. L., Bremer, A. A., Berglund, L., Nakajima, K., Havel, P. J., & Stanhope, K. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070913 · Cited by 26 · see citing works

Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease

Ikeda, S., Sugihara, T., Hoshino, Y., Matsuki, Y., Nagahara, T., Okano, J., Kitao, S., Fujioka, Y., Yamamoto, K., & Isomoto, H. (2020) · Yonago acta medica · doi:10.33160/yam.2020.08.009 · Cited by 25 · see citing works

Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients

Goto, H., Iseri, K., & Hida, N. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad248 · Cited by 24 · see citing works

Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention

Orabi, D., Berger, N. A., & Brown, J. M. (2021) · Cancers · doi:10.3390/cancers13143473 · Cited by 24 · see citing works

An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α

Sharma, S., Sharma, D., Dhobi, M., Wang, D., & Tewari, D. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04755-7 · Cited by 23 · see citing works

Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

Bołdys, A., Bułdak, Ł., Maligłówka, M., Surma, S., & Okopień, B. (2023) · Medicina · doi:10.3390/medicina59101789 · Cited by 23 · see citing works

Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial

Doi, T., Langsted, A., & Nordestgaard, B. G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117556 · Cited by 23 · see citing works

Role of MASLD in CVD: A review of emerging treatment options

Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 23 · see citing works

Anti-diabetic drugs and NASH: from current options to promising perspectives

Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 21 · see citing works

Real ambient particulate matter-induced lipid metabolism disorder: Roles of peroxisome proliferators-activated receptor alpha

Xu, Z., Shi, L., Li, D., Wu, Q., Zhang, Y., Gao, M. M., Ji, A., Jiang, Q., Chen, R., Zhang, R., et al. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113173 · Cited by 21 · see citing works

Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases

Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21 · see citing works

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 18 · see citing works

An Increased Plasma Level of ApoCIII-Rich Electronegative High-Density Lipoprotein May Contribute to Cognitive Impairment in Alzheimer’s Disease

Chan, H., Ke, L., Lu, H.-T., Weng, S., Chan, H., Law, S., Lin, I., Chang, C., Lu, Y., Chen, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8120542 · Cited by 18 · see citing works

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

Nakamura, A., Kagaya, Y., Saito, H., Kanazawa, M., Sato, K., Miura, M., Kondo, M., & Endo, H. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63659 · Cited by 18 · see citing works

Lessons from PROMINENT and prospects for pemafibrate

Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16 · see citing works

SPPARM alpha: the Lazarus effect

Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 16 · see citing works

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 16 · see citing works

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Komiya, I., Yamamoto, A., Sunakawa, S., & Wakugami, T. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01434-8 · Cited by 16 · see citing works

Is hypertriglyceridemia atherogenic?

Huet, F., Roubille, C., & Roubille, F. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000622 · Cited by 15 · see citing works

Rounding the corner on residual risk: Implications of REDUCE‐IT for omega‐3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease

Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 15 · see citing works

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60764 · Cited by 14 · see citing works

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study

Ono, H., Atsukawa, M., Tsubota, A., Arai, T., Suzuki, K. M., Higashi, T., Kitamura, M., Shioda, K., Kawano, T., Yoshida, Y., et al. (2024) · JGH Open · doi:10.1002/jgh3.13057 · Cited by 14 · see citing works

Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial

Yamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14227 · Cited by 14 · see citing works

Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study

Kito, K., Nomoto, H., Sakuma, I., Nakamura, A., Cho, K. Y., Kameda, H., Miya, A., Omori, K., Yanagiya, S., Handa, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110091 · Cited by 14 · see citing works

Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 14 · see citing works

Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice

Suto, K., Fukuda, D., Shinohara, M., Ganbaatar, B., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K., & Sata, M. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.61101 · Cited by 14 · see citing works

Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

Khan, M. S., Ghumman, G. M., Baqi, A., Shah, J., Aziz, M., Mir, T., Tahir, A., Katragadda, S., Singh, H., Taleb, M., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00593-6 · Cited by 11 · see citing works

Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate

Wang, H., Li, H., Zhou, Y., Liu, J., Wang, F., & Zhao, Q. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191126102943 · Cited by 11 · see citing works

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap

Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 11 · see citing works

Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol

Iwaki, M., Kobayashi, T., Nogami, A., Ogawa, Y., Imajo, K., Sakai, E., Nakada, Y., Koyama, S., Kurihashi, T., Oza, N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088862 · Cited by 10 · see citing works

Management of Mild-to-Moderate Hypertriglyceridemia

Pulipati, V. P., Brinton, E. A., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.003 · Cited by 9 · see citing works

Downregulated level of insulin in COPD patients during AE; role beyond glucose control?

Ruan, W., Yan, C., Zhu, H., Wang, S., Jia, X., Shao, L., Xu, Z., & Ying, K. (2019) · International Journal of COPD · doi:10.2147/copd.s197164 · Cited by 9 · see citing works

Metabolic Variation Dictates Cardiac Pathogenesis in Patients With Tetralogy of Fallot

Liu, J., Kong, S., Song, S., Dong, H., Zhang, Z., & Fan, T. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2021.819195 · Cited by 9 · see citing works

Pemafibrate suppresses oxidative stress and apoptosis under cardiomyocyte ischemia‑reperfusion injury in type 1 diabetes mellitus

Li, W., Xu, J., Guo, X., Xia, X., & Sun, Y. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9762 · Cited by 9 · see citing works

Selective PPARα Modulator (SPPARMα) in the Era of the MASLD Pandemic: Current Insights and Future Prospects

Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8 · see citing works

Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)

Seki, M., Nakano, T., Tanaka, S., Matsukuma, Y., Funakoshi, K., Ohkuma, T., & Kitazono, T. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02322-4 · Cited by 8 · see citing works

Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial

Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Yamasaki, S., Suganami, H., & Ishibashi, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64677 · Cited by 8 · see citing works

843-P: Effects of Pemafibrate on Glucose Metabolism in Adults with Type 2 Diabetes and Hypertriglyceridemia—Subanalysis of the PARM-T2D Study

Nomoto, H., Kito, K., Nakamura, A., Kameda, H., Omori, K., Yanagiya, S., Iesaka, H., OE, Y., Kawata, S., Atsumi, T., et al. (2023) · Diabetes · doi:10.2337/db23-843-p

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13686 · Cited by 46 · see citing works

Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes

Bando, H., Taneda, S., & Manda, N. (2021) · JMA Journal · doi:10.31662/jmaj.2020-0104 · Cited by 5 · see citing works

IDF21-0056 Effects of pemafibrate on lipid metabolism in patients with hypertriglyceridemia complicated with type 2 diabetes

Kito, K., Nomoto, H., Sakuma, I., Nakamura, A., Cho, K. Y., Taneda, S., Takeuchi, J., Nagai, S., Kurihara, Y., Aoki, S., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109704

Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study

Kito, K., Nomoto, H., Sakuma, I., Nakamura, A., Cho, K. Y., Kameda, H., Miya, A., Omori, K., Yanagiya, S., Handa, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110091 · Cited by 14 · see citing works